Biomarkers and risk factors for the early prediction of immune-related adverse events: a review
In recent years, immunotherapy has been widely used to treat patients with malignant tumors. While immune checkpoint inhibitors (ICIs) significantly improve the prognosis of cancer patients, the incidence of immune-related adverse events (irAEs) is increasing. Not only can irAEs accumulate in multip...
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
Taylor & Francis Group
2022-01-01
|
| coleção: | Human Vaccines & Immunotherapeutics |
| Assuntos: | |
| Acesso em linha: | http://dx.doi.org/10.1080/21645515.2021.2018894 |